Back to Results
First PageMeta Content
Alkylating antineoplastic agents / Antiemetics / Chemotherapy-induced nausea and vomiting / Prodrugs / Cyclophosphamide / 5-HT3 antagonist / Chemotherapy / Cisplatin / Medicine / Chemistry / Oncology


P11444 - ASCO2014 MEC and HEC
Add to Reading List

Document Date: 2014-05-30 12:01:38

Open Document

File Size: 303,15 KB

Share Result on Facebook

City

Boston / Chicago / Waltham / Matrahaza / /

Company

Either Treatment Group / 2TESARO Inc. / AEs / HEC2 Control Conclusions / Table / /

Country

Hungary / United States / Italy / /

Event

FDA Phase / /

Facility

S.G. Moscati Hospital / Tufts Medical Center / University Teaching Hospital / /

IndustryTerm

control groups / rolapitant / control / prevention of CINV in cancer / /

MedicalCondition

Mediastinal Disorders / tumor / General Disorders / cancer / Nervous System Disorders / headache / Chemotherapy-Induced Nausea / neutropenia / nausea / Vomiting / fatigue / diarrhea / dizziness / constipation / Gastrointestinal Disorders / Nervous System Disorders General Disorders / skin and subcutaneous tissue disorders / /

MedicalTreatment

Chemotherapy / /

Organization

World Health Organization / C. Gridelli4 1Matrahaza Healthcare Center / S.G. Moscati Hospital / Medical Center / University Teaching Hospital / /

/

Position

General / Breast Lung Colon/Rectum Head / Nervous System Disorders General / /

Product

Granisetron / Carboplatin / cisplatin / Dexamethasone / cytarabine / Cyclophosphamide / ifosfamide / Rescue Medication / HEC1 / Control Total Rolapitant / study drug / /

ProvinceOrState

Illinois / Massachusetts / /

Region

South Africa / /

Technology

Chemotherapy / /

SocialTag